Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. [electronic resource]
Producer: 20101116Description: 1536-42 p. digitalISSN:- 1029-2403
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacokinetics
- Bone Marrow Cells -- drug effects
- Chemistry, Pharmaceutical
- Cytarabine -- administration & dosage
- DNA-Binding Proteins -- physiology
- Daunorubicin -- administration & dosage
- Dosage Forms
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Synergism
- Female
- Flow Cytometry
- Humans
- Liposomes
- Maximum Tolerated Dose
- Mice
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Survival Rate
- Tissue Distribution
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.